<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Wiskirchen, Dora E.</dc:creator>
  <dc:creator>Nordmann, Patrice</dc:creator>
  <dc:creator>Crandon, Jared L.</dc:creator>
  <dc:creator>Nicolau, David P.</dc:creator>
  <dc:date>2014-02-19</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Doripenem and ertapenem have demonstrated efficacy against several NDM-1- producing isolates &lt;em&gt;in vivo&lt;/em&gt;, despite having high MICs. In this study, we  sought to further characterize the efficacy profiles of humanized regimens of standard  (500 mg given every 8 h) and high-dose, prolonged infusion of doripenem (2 g given  every 8 h, 4-h infusion) and 1 g of ertapenem given intravenously every 24 h and the  comparator regimens of ceftazidime at 2 g given every 8 h (2-h infusion), levofloxacin  at 500 mg every 24 h, and aztreonam at 2 g every 6 h (1-h infusion) against a wider  range of isolates in a murine thigh infection model. An isogenic wild-type strain and  NDM-1-producing Klebsiella pneumoniae and eight clinical NDM-1-producing  members of the family Enterobacteriaceae were tested in immunocompetent- and  neutropenic-mouse models. The wild-type strain was susceptible to all of the agents,  while the isogenic NDM-1-producing strain was resistant to ceftazidime, doripenem,  and ertapenem. Clinical NDM-1-producing strains were resistant to nearly all five of  the agents (two were susceptible to levofloxacin). In immunocompetent mice, all of the  agents produced ≥1-log₁₀ CFU reductions of the isogenic wild-type and NDM-1- producing strains after 24 h. Minimal efficacy of ceftazidime, aztreonam, and  levofloxacin against the clinical NDM-1-producing strains was observed. However,  despite &lt;em&gt;in vitro&lt;/em&gt; resistance, ≥1-log₁₀ CFU reductions of six of eight clinical  strains were achieved with high-dose, prolonged infusion of doripenem and  ertapenem. Slight enhancements of doripenem activity over the standard doses were  obtained with high-dose, prolonged infusion for three of the four isolates tested.  Similar efficacy observations were noted in neutropenic mice. These data suggest that  carbapenems are a viable treatment option for infections caused by NDM-1-producing  Enterobacteriaceae.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/303549</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/303549/files/nor_veh.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1128/AAC.01946-13</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>Antimicrobial Agents and Chemotherapy. - 2014, vol. 58, no. 3, p. 1671-1677</dc:source>
  <dc:subject>info:eu-repo/classification/udc/61</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">&lt;i&gt;In Vivo&lt;/i&gt; Efficacy of Human Simulated Regimens of Carbapenems and Comparator Agents against NDM-1-Producing Enterobacteriaceae</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
